The Pharm Exec staff

Big Pharma employment dropped by 3 percent in the decade 2003–2013, allaying fears that industry consolidation and restructuring would lead to significantly reduced headcounts and payrolls, a report by EP Vantage reveals.

A new report from GlobalData states that the increase of biosimilars will have a negative impact on the biologics market after 2019.

The European Medicine Agency’s Pharmacovigilance and Risk Assessment Committee (PRAC) has started a review to evaluate the cardiovascular risks with systemic ibuprofen medicines.

The future of GSK’s Tykerb (lapatinib) in the breast cancer market is unclear, after the combination of Tykerb and Herceptin in the large Phase III trial.

Europe’s main pharma industry bodies - EFPIA, EGA, EuropaBio, AESGP and EUCOPE - have issued a joint statement to express concern about “the increasing financial burden of regulatory costs incurred since the adoption of the pharmacovigilance package in 2010?.

In this short video, Brianna Cayo-Cotter, Change.org’s managing director of communications, talks to Pharm Exec about how advocacy organizations and individual patients are getting more involved in every facet of the healthcare system, from drug R&D, to federal and state policy, all fueled by the hour-to-hour passion of living with a disease.

Four class representatives have been added to a class-action gender-discrimination employment suit originally filed last May against Merck & Co. in New Jersey.

Actavis and Forest Laboratories have entered into a definitive agreement under which Actavis will acquire Forest for a combination of cash and equity valued at approximately $25 billion or $89.48 per Forest share, Actavis announced in a press release.

The Affordable Care Act (ACA) has sent biopharmaceutical companies scrambling to understand how their business model, including its ability to innovate, will change as healthcare reform moves forward.

Accenture has launched the latest version of its annual study of the biopharmaceutical industry.

Thirty-five out of every 100 job applicants in the pharmaceutical or clinical trial space in India “are lying about their credentials”, says a report by Delhi-based employee screening firm AuthBridge.

Pleas for compassionate use access are on the increase, and Change.org is giving patients an audience.

The European Medicines Agency (EMA), in agreement with the European Commission, has released an updated question and answer document clarifying a number of issues related to the new categories of variations to the terms of marketing authorizations that were introduced by the agency in August 2013.

The European type 2 diabetes market earned revenues of €9.50 billion in 2009 and is estimated to reach €15.46 billion in 2017 (CAGR 3.8 percent), according to new research by Frost & Sullivan.

Strong, skilled management is on the agenda as never before. Find out who made 2010's roster of high-potential change masters-and how they plan to lead the industry through the turbulent times ahead.